We propose that, based on both its expression pattern and its demonstrated functional role, FRAT1 may also be useful as a valuable biomarker for the molecular diagnosis of glioma and a promising candidate target for glioma therapy. This evidence concerns the gene FRAT1 and central nervous system cancer.